The @US_FDA has approved #Pixclara as the first #PETimaging agent for #glioma. ow.ly/agtH50ZRctC @TelixPharma @NeuroOnc @AANmember

🧠 How is technology reshaping care for people with #MovementDisorders? The latest issue of Practical Neurology, with Guest Medical Editor Kimmy Su, MD, PhD, explores advances in wearable devices, gait and speech technologies, #tremor-reducing devices, #DeepBrainStimulation, and more. Read the new issue today: ow.ly/LkUi50ZQNJ4 @AANmember @movedisorder @ParkinsonDotOrg @MichaelJFoxOrg @UW #DBS #Parkinson

The @US_FDA granted Priority Review to an sBLA for #Enspryng (#satralizumab) for treatment of people with #MOGAD, with a decision expected in January of 2027. ow.ly/zCLe50ZQGf5 @Roche @mssociety @AANmember

The @US_FDA approved #Isembyld (#apitegromab) for the treatment of people aged 2 years and older with #Spinal_Muscular_Atrophy who are receiving survival motor neuron 2–targeted treatment. ow.ly/Hin150ZQmWw @CureSMA @AANmember @ScholarRock #SMA

🧠🎙️ Can #Alzheimer's be treated before #cognitive symptoms appear? In an episode of the #NeuroFrontiers podcast series, Geoff Kerchner, MD, (@Roche discusses findings from the PrevenTRON trial evaluating #trontinimab treatment for people with preclinical AD, including its use of #Brainshuttle technology, p-tau217 testing for participant identification, and the focus on delaying clinical progression. ow.ly/kiCC50ZOWvn @alzassociation @AANmember

Delpacibart etedesiran (del-desiran) did not significantly improve video hand opening time vs placebo in the Phase 3 HARBOR trial of people with myotonic dystrophy type 1 (DM1), according to @Novartis ow.ly/3cIz50ZPfTq @MDAorg @MyotonicStrong #DM1 #MyotonicDystrophy #Neuromuscular

Treatment with #cebranopadol, an investigational dual NOP/MOP receptor agonist, was associated with statistically significant reductions in pain intensity in participants compared with placebo in 2 phase 3 surgical #pain studies presented at #PAINWeek 2026. ow.ly/MTyC50ZOW9w #nonopioid @Adneuris @ASRA_Society @PAINWeek

Earlier age at #menopause was associated with faster global #cognitive decline and episodic memory decline in older women, as well as shorter time to #Alzheimer's diagnosis in the full cohort. ow.ly/BG2m50ZO5Sg @JAMANetworkOpen @AANmember @alzassociation

In results of the phase 3 LUNA trial, adults with menstrual #migraine treated with #Qulipta/#atogepant showed greater reductions in migraine days during the perimenstrual period than those receiving placebo. ow.ly/lPEk50ZO5K8 @abbvie @ahsheadache @NHF @amfmigraine @AANmember

🎨 The cover for the August issue of Practical Neurology features artwork by Paul Kolker, MD, JD. ow.ly/pFJj50ZNsEg The artwork depicts the philosopher Martin Buber, whose seminal work “I and Thou” profoundly influenced Dr. Kolker’s artistic thinking. Additional details about Dr. Kolker and his work may be found on ow.ly/uyVQ50ZNsEf. @AANmember @AMA_ReallyNow

Treatment with #gefurulimab was associated with significant improvements in daily function and muscle strength vs placebo in adults with AChR+ #gMG. Data published in @JAMANeuro. ow.ly/sas650ZN21b @MyastheniaOrg @MyastheniaGNews @AANmember

🧠🎙️ Could a novel oral therapy offer a new approach to treating obstructive sleep #apnea? Dr. Patrick J. Strollo Jr discusses phase 3 SynAIRgy clinical trial data for AD109, an investigational once-nightly oral treatment for #OSA, in the latest episode of the Neurology: Disease Deep Dive podcast series. ow.ly/Lzjn50ZMQ9H @PittDeptofMed @AASMorg @AANmember

Long-term residential exposure to road traffic noise was associated with higher risk of #Parkinson disease in a nationwide Danish cohort study. ow.ly/4v3b50ZMq0w @movedisorder @AANmember @ParkinsonDotOrg @MichaelJFoxOrg

The use of generative #AI in #neurology practice raises important questions about patient safety, liability, #HIPAA compliance, and the standard of care. A practical review article by Nina Riggins, MD, PhD (@NinaRiggins) and Lorenzo Paris, JD explores how neurologists can responsibly integrate #GenAI into clinical practice while navigating an evolving legal landscape. ow.ly/ExC350ZM3ml @AANmember @AmerMedicalAssn @VAPaloAlto

Tx with the investigational factor XIa inhibitor #milvexian did not reduce #cardiovascular death, myocardial infarction, or ischemic #stroke when added to #antiplatelet therapy after acute coronary syndrome in the phase 3 LIBREXIA ACS trial. ow.ly/IxnK50ZLGEO @American_Stroke @American_Heart @EVToday @JNJNews @bmsnews

The @US_FDA has approved #Zanvastro (#zilganersen) injection for the treatment of pediatric and adult patients with #Alexander_disease. ow.ly/IfGz50ZL3JQ @ionispharma @ChildNeuroSoc @AmEpilepsySoc #AlexanderDisease

Real-world data suggest approximately two-thirds of children aged 2 to 4 years with #RettSyndrome remained persistent on #Daybue (#trofinetide) during available follow-up. ow.ly/S0g150ZJwVN @AcadiaPharma @AANmember @AmEpilepsySoc

Treatment with #valiltramiprosate (#ALZ801 @Alzheon) was associated with reductions in plasma #Alzheimer's biomarkers, including p-tau217, in APOE4/4 homozygotes with early AD. ow.ly/6mgW50ZJvNE @TheADDF @alzassociation @AANmember

Fraud, waste, and abuse laws affect everyday #neurology practice, making compliance essential to both patient care and professional protection. A practical review article by Rachel V Rose, JD, MBA, and Joseph S Kass, MD, JD, FAAN (@JosephKass4) discusses the False Claims Act, Anti-Kickback Statute, and the compliance strategies that help protect both patients and clinicians. ow.ly/G0Gc50ZJvBt @AANmember #HealthcareCompliance #MedicalLegal @bcmhouston